NEKTAR IMMUNIVATION
explore our pipeline
The Nektar clinical trials are investigating multiple pathways to engage the immunity cycle to fight cancer.
Search our active clinical development pipeline in immuno-oncology.
Select a tumor type, phase of study, or molecule to begin.
Molecule
Patient Population
Phase
Partner
Registrational
Bempegaldesleukin
(BEMPEG; NKTR-214)
+ nivolumab (NIVO)
PIVOT-IO 001*
(BEMPEG; NKTR-214)
+ nivolumab (NIVO)
PIVOT-IO 001*
1L unresectable, inoperable, or
metastatic melanoma
metastatic melanoma
Phase 3 registrational trial
BEMPEG + NIVO
PIVOT-IO 009*
PIVOT-IO 009*
Neoadjuvant +
adjuvant muscle-invasive bladder cancer in cis-ineligible patients
adjuvant muscle-invasive bladder cancer in cis-ineligible patients
Phase 3 registrational trial
BEMPEG + NIVO PIVOT-10†
1L locally advanced or metastatic urothelial cancer in cis-ineligible patients
Phase 2 registrational trial
Phase 1 and 2
BEMPEG + NIVO + tyrosine kinase inhibitor
PIVOT-IO 011*
PIVOT-IO 011*
1L advanced or metastatic renal cell carcinoma
Phase 1/2
BEMPEG + NIVO
OR BEMPEG + NIVO + IPI
PIVOT-02†
OR BEMPEG + NIVO + IPI
PIVOT-02†
1L - 3L select advanced solid tumors
Phase 1/2
BEMPEG + NIVO
PIVOT-IO 020*
PIVOT-IO 020*
Children, adolescents, and young adults with recurrent or treatment-resistant cancer
Phase 1/2
BEMPEG +
pembrolizumab
PROPEL†
pembrolizumab
PROPEL†
1L - 2L locally advanced or metastatic NSCLC, melanoma, urothelial carcinoma, SCCHN, and HCC (dose optimization); 1L locally advanced or metastatic NSCLC (dose expansion)
Phase 1/2
NKTR-262 (TLR 7/8
agonist) + BEMPEG
+ NIVO or NKTR-262 (TLR 7/8 agonist) + BEMPEG REVEAL †
agonist) + BEMPEG
+ NIVO or NKTR-262 (TLR 7/8 agonist) + BEMPEG REVEAL †
Locally advanced or metastatic solid tumors
Phase 1/2
NKTR-255 (IL-15 agonist) or NKTR-255 (IL-15 agonist) + daratumumab subcutaneous or NKTR-255 (IL-15 agonist) + rituximab†
R/R non-Hodgkin's
lymphoma, R/R
multiple myeloma
lymphoma, R/R
multiple myeloma
Phase 1
cis=cisplatin; CRPC=castrate-resistant prostate cancer; HCC=hepatocellular carcinoma; NSCLC=non-small cell lung cancer; R/R=relapsed/refractory; SCCHN=squamous cell carcinoma of the head and neck.
Third-party trademarks used herein are trademarks of their respective owners.
*Sponsored by Bristol-Myers Squibb.
†Sponsored by Nektar Therapeutics.
‡Sponsored by Vaccibody AS.
